LIVIVO - Search results -

Search results

Result 1 - 10 of total 15

Search options

Article: NK Cell-Fc Receptors Advance Tumor Immunotherapy.

Sanseviero, Emilio

2019 Volume 8, Issue 10

Abstract: Immunotherapy has revolutionized the treatment of cancer patients. Among immunotherapeutic approaches, antibodies targeting immune checkpoint inhibitors Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are ... ...

Abstract	Immunotherapy has revolutionized the treatment of cancer patients. Among immunotherapeutic approaches, antibodies targeting immune checkpoint inhibitors Programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) are approved for treatment of metastatic melanoma and are in clinical trials for a variety of other cancers. The contribution of Natural Killer (NK) cells to the efficacy of immune checkpoint inhibitors is becoming more evident. Enhancing both T and NK cell function in cancer could result in a robust and durable response. Along with the ability to directly kill tumor cells, NK cells can mediate antibody-dependent cellular cytotoxicity (ADCC) given the expression of Fragment Crystallizable (Fc) receptors. Promising novel antibodies modified with improved Fc-receptor-mediated functions or Fc-engagers to kill target cells have been tested in pre-clinical models with considerable results. Combination therapies with immune-therapeutic antibodies with enhancers of NK-cell Fc-receptor-mediated function can be exploited to increase the efficacy of these antibodies. Herein, I discuss possible strategies to improve the success of immunotherapy by boosting NK cell function.
Language	English
Publishing date	2019-10-12
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2662592-1
ISSN	2077-0383
ISSN	2077-0383
DOI	10.3390/jcm8101667
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity.

Veglia, Filippo / Sanseviero, Emilio / Gabrilovich, Dmitry I

Nature reviews. Immunology

2021 Volume 21, Issue 8, Page(s) 485–498

Abstract: Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes with potent immunosuppressive activity. They are implicated in the regulation of immune responses in many pathological conditions and are closely associated ... ...

Abstract	Myeloid-derived suppressor cells (MDSCs) are pathologically activated neutrophils and monocytes with potent immunosuppressive activity. They are implicated in the regulation of immune responses in many pathological conditions and are closely associated with poor clinical outcomes in cancer. Recent studies have indicated key distinctions between MDSCs and classical neutrophils and monocytes, and, in this Review, we discuss new data on the major genomic and metabolic characteristics of MDSCs. We explain how these characteristics shape MDSC function and could facilitate therapeutic targeting of these cells, particularly in cancer and in autoimmune diseases. Additionally, we briefly discuss emerging data on MDSC involvement in pregnancy, neonatal biology and COVID-19.
MeSH term(s)	Autoimmune Diseases/immunology ; Autoimmune Diseases/metabolism ; COVID-19/immunology ; COVID-19/prevention & control ; COVID-19/virology ; Cytokines/immunology ; Cytokines/metabolism ; Humans ; Monocytes/immunology ; Monocytes/metabolism ; Myeloid Cells/immunology ; Myeloid Cells/metabolism ; Myeloid-Derived Suppressor Cells/immunology ; Myeloid-Derived Suppressor Cells/metabolism ; Neoplasms/immunology ; Neoplasms/metabolism ; Neutrophils/immunology ; Neutrophils/metabolism ; SARS-CoV-2/immunology ; SARS-CoV-2/physiology
Chemical Substances	Cytokines
Language	English
Publishing date	2021-02-01
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2062776-2
ISSN	1474-1741 ; 1474-1733
ISSN (online)	1474-1741
ISSN	1474-1733
DOI	10.1038/s41577-020-00490-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5565: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 34: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Isolation and Phenotyping of Splenic Myeloid-Derived Suppressor Cells in Murine Cancer Models.

Sanseviero, Emilio / Kim, Rina / Gabrilovich, Dmitry I

Methods in molecular biology (Clifton, N.J.)

2020 Volume 2236, Page(s) 19–28

Abstract: Myeloid-derived suppressor cells (MDSC) are immunosuppressive myeloid cells that accumulate in tumor sites and peripheral lymphoid organs such as the spleen. In murine cancer models, the spleen is a major reservoir for MDSC, representing an easily ... ...

Abstract	Myeloid-derived suppressor cells (MDSC) are immunosuppressive myeloid cells that accumulate in tumor sites and peripheral lymphoid organs such as the spleen. In murine cancer models, the spleen is a major reservoir for MDSC, representing an easily accessible tissue from which to isolate high numbers of these cell population for downstream applications. Here we describe an efficient method to phenotype as well as to isolate and assess the functionality of murine splenic MDSC.
MeSH term(s)	Animals ; Cell Separation/methods ; Disease Models, Animal ; Immunophenotyping/methods ; Mice ; Monocytes/pathology ; Myeloid-Derived Suppressor Cells/pathology ; Neoplasms/pathology ; Neutrophils/pathology ; Phenotype ; Spleen/pathology
Language	English
Publishing date	2020-11-25
Publishing country	United States
Document type	Journal Article
ISSN	1940-6029
ISSN (online)	1940-6029
DOI	10.1007/978-1-0716-1060-2_3
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic.

Grover, Amit / Sanseviero, Emilio / Timosenko, Elina / Gabrilovich, Dmitry I

Cancer discovery

2021 Volume 11, Issue 11, Page(s) 2693–2706

Abstract: Myeloid-derived suppressor cells (MDSC) are important regulators of immune responses in cancer. They represent a relatively stable form of pathologic activation of neutrophils and monocytes and are characterized by distinct transcriptional, biochemical, ... ...

Abstract	Myeloid-derived suppressor cells (MDSC) are important regulators of immune responses in cancer. They represent a relatively stable form of pathologic activation of neutrophils and monocytes and are characterized by distinct transcriptional, biochemical, functional, and phenotypical features. The close association of MDSCs with clinical outcomes in cancer suggests that these cells can be an attractive target for therapeutic intervention. However, the complex nature of MDSC biology represents a substantial challenge for the development of selective therapies. Here, we discuss the mechanisms regulating MDSC development and fate and recent research advances that have demonstrated opportunities for therapeutic regulation of these cells. SIGNIFICANCE: MDSCs are attractive therapeutic targets because of their close association with negative clinical outcomes in cancer and established biology as potent immunosuppressive cells. However, the complex nature of MDSC biology presents a substantial challenge for therapeutic targeting. In this review, we discuss those challenges and possible solutions.
MeSH term(s)	Humans ; Monocytes ; Myeloid-Derived Suppressor Cells ; Neoplasms ; Neutrophils
Language	English
Publishing date	2021-10-11
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2625242-9
ISSN	2159-8290 ; 2159-8274
ISSN (online)	2159-8290
ISSN	2159-8274
DOI	10.1158/2159-8290.CD-21-0764
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6916: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Syntaphilin Regulates Neutrophil Migration in Cancer.

Fu, Shuyu / Deng, Hui / Bertolini, Irene / Perego, Michela / Chen, Eric S / Sanseviero, Emilio / Mostafa, Ali / Alicea-Torres, Kevin / Garcia-Gerique, Laura / Stone, Erica L / Kossenkov, Andrew V / Schug, Zachary T / Nam, Brian / Mulligan, Charles / Altieri, Dario C / Nefedova, Yulia / Gabrilovich, Dmitry I

Cancer immunology research

2022 Volume 11, Issue 3, Page(s) 278–289

Abstract: Pathologically activated neutrophils (PMN) with immunosuppressive activity, which are termed myeloid-derived suppressor cells (PMN-MDSC), play a critical role in regulating tumor progression. These cells have been implicated in promoting tumor metastases ...

Abstract	Pathologically activated neutrophils (PMN) with immunosuppressive activity, which are termed myeloid-derived suppressor cells (PMN-MDSC), play a critical role in regulating tumor progression. These cells have been implicated in promoting tumor metastases by contributing to premetastatic niche formation. This effect was facilitated by enhanced spontaneous migration of PMN from bone marrow to the premetastatic niches during the early-stage of cancer development. The molecular mechanisms underpinning this phenomenon remained unclear. In this study, we found that syntaphilin (SNPH), a cytoskeletal protein previously known for anchoring mitochondria to the microtubule in neurons and tumor cells, could regulate migration of PMN. Expression of SNPH was decreased in PMN from tumor-bearing mice and patients with cancer as compared with PMN from tumor-free mice and healthy donors, respectively. In Snph-knockout (SNPH-KO) mice, spontaneous migration of PMN was increased and the mice showed increased metastasis. Mechanistically, in SNPH-KO mice, the speed and distance travelled by mitochondria in PMN was increased, rates of oxidative phosphorylation and glycolysis were elevated, and generation of adenosine was increased. Thus, our study reveals a molecular mechanism regulating increased migratory activity of PMN during cancer progression and suggests a novel therapeutic targeting opportunity.
MeSH term(s)	Animals ; Mice ; Cell Movement ; Membrane Proteins/metabolism ; Myeloid-Derived Suppressor Cells/metabolism ; Neoplasms/pathology ; Nerve Tissue Proteins ; Neutrophils/metabolism
Chemical Substances	Membrane Proteins ; Nerve Tissue Proteins ; Snph protein, mouse
Language	English
Publishing date	2022-11-11
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2732489-8
ISSN	2326-6074 ; 2326-6066
ISSN (online)	2326-6074
ISSN	2326-6066
DOI	10.1158/2326-6066.CIR-22-0035
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 7022: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment.

Hardaker, Elizabeth L / Sanseviero, Emilio / Karmokar, Ankur / Taylor, Devon / Milo, Marta / Michaloglou, Chrysis / Hughes, Adina / Mai, Mimi / King, Matthew / Solanki, Anisha / Magiera, Lukasz / Miragaia, Ricardo / Kar, Gozde / Standifer, Nathan / Surace, Michael / Gill, Shaan / Peter, Alison / Talbot, Sara / Tohumeken, Sehmus /

Fryer, Henderson / Mostafa, Ali / Mulgrew, Kathy / Lam, Carolyn / Hoffmann, Scott / Sutton, Daniel / Carnevalli, Larissa / Calero-Nieto, Fernando J / Jones, Gemma N / Pierce, Andrew J / Wilson, Zena / Campbell, David / Nyoni, Lynet / Martins, Carla P / Baker, Tamara / Serrano de Almeida, Gilberto / Ramlaoui, Zainab / Bidar, Abdel / Phillips, Benjamin / Boland, Joseph / Iyer, Sonia / Barrett, J Carl / Loembé, Arsene-Bienvenu / Fuchs, Serge Y / Duvvuri, Umamaheswar / Lou, Pei-Jen / Nance, Melonie A / Gomez Roca, Carlos Alberto / Cadogan, Elaine / Critichlow, Susan E / Fawell, Steven / Cobbold, Mark / Dean, Emma / Valge-Archer, Viia / Lau, Alan / Gabrilovich, Dmitry I / Barry, Simon T

Nature communications

2024 Volume 15, Issue 1, Page(s) 1700

Abstract: The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that ... ...

Abstract	The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical benefit in melanoma and lung cancer patients who progressed on immunotherapy. Here we show that modelling of intermittent ceralasertib treatment in mouse tumor models reveals CD8
MeSH term(s)	Humans ; Animals ; Mice ; CD8-Positive T-Lymphocytes ; B7-H1 Antigen ; Tumor Microenvironment ; Cell Line, Tumor ; Immunotherapy ; Disease Models, Animal ; Neoplasms ; Ataxia Telangiectasia Mutated Proteins ; Indoles ; Morpholines ; Pyrimidines ; Sulfonamides
Chemical Substances	ceralasertib (85RE35306Z) ; B7-H1 Antigen ; ATR protein, human (EC 2.7.11.1) ; Ataxia Telangiectasia Mutated Proteins (EC 2.7.11.1) ; Indoles ; Morpholines ; Pyrimidines ; Sulfonamides
Language	English
Publishing date	2024-02-24
Publishing country	England
Document type	Journal Article
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-024-45996-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Myeloid-Derived Suppressor Cells Are a Major Source of Wnt5A in the Melanoma Microenvironment and Depend on Wnt5A for Full Suppressive Activity.

Douglass, Stephen M / Fane, Mitchell E / Sanseviero, Emilio / Ecker, Brett L / Kugel, Curtis H / Behera, Reeti / Kumar, Vinit / Tcyganov, Evgenii N / Yin, Xiangfan / Liu, Qin / Chhabra, Yash / Alicea, Gretchen M / Kuruvilla, Rejji / Gabrilovich, Dmitry I / Weeraratna, Ashani T

Cancer research

2020 Volume 81, Issue 3, Page(s) 658–670

Abstract: Metastatic dissemination remains a significant barrier to successful therapy for melanoma. Wnt5A is a potent driver of invasion in melanoma and is believed to be secreted from the tumor microenvironment (TME). Our data suggest that myeloid-derived ... ...

Abstract	Metastatic dissemination remains a significant barrier to successful therapy for melanoma. Wnt5A is a potent driver of invasion in melanoma and is believed to be secreted from the tumor microenvironment (TME). Our data suggest that myeloid-derived suppressor cells (MDSC) in the TME are a major source of Wnt5A and are reliant upon Wnt5A for multiple actions. Knockdown of Wnt5A specifically in the myeloid cells demonstrated a clear decrease in Wnt5A expression within the TME
MeSH term(s)	Animals ; Antigens, CD/metabolism ; Arginase/metabolism ; Cell Line, Tumor ; Female ; Lung Neoplasms/secondary ; Lymphocytes, Tumor-Infiltrating/metabolism ; Male ; Melanoma/metabolism ; Melanoma/secondary ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Myeloid-Derived Suppressor Cells/immunology ; Myeloid-Derived Suppressor Cells/metabolism ; Neoplasm Invasiveness ; Programmed Cell Death 1 Receptor/metabolism ; T-Lymphocytes, Regulatory/metabolism ; Transforming Growth Factor beta1/metabolism ; Tumor Microenvironment ; Wnt-5a Protein/metabolism
Chemical Substances	Antigens, CD ; CD223 antigen ; PDCD1 protein, human ; Programmed Cell Death 1 Receptor ; Transforming Growth Factor beta1 ; Wnt-5a Protein ; Wnt5a protein, mouse ; Arginase (EC 3.5.3.1)
Language	English
Publishing date	2020-12-01
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	1432-1
ISSN	1538-7445 ; 0008-5472
ISSN (online)	1538-7445
ISSN	0008-5472
DOI	10.1158/0008-5472.CAN-20-1238
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uh III Zs.135/5: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway.

Nature communications

2021 Volume 12, Issue 1, Page(s) 1717

Abstract: Myeloid-derived suppressor cells (MDSC) are pathologically activated neutrophils and monocytes with potent immune suppressive activity. These cells play an important role in accelerating tumor progression and undermining the efficacy of anti-cancer ... ...

Abstract	Myeloid-derived suppressor cells (MDSC) are pathologically activated neutrophils and monocytes with potent immune suppressive activity. These cells play an important role in accelerating tumor progression and undermining the efficacy of anti-cancer therapies. The natural mechanisms limiting MDSC activity are not well understood. Here, we present evidence that type I interferons (IFN1) receptor signaling serves as a universal mechanism that restricts acquisition of suppressive activity by these cells. Downregulation of the IFNAR1 chain of this receptor is found in MDSC from cancer patients and mouse tumor models. The decrease in IFNAR1 depends on the activation of the p38 protein kinase and is required for activation of the immune suppressive phenotype. Whereas deletion of IFNAR1 is not sufficient to convert neutrophils and monocytes to MDSC, genetic stabilization of IFNAR1 in tumor bearing mice undermines suppressive activity of MDSC and has potent antitumor effect. Stabilizing IFNAR1 using inhibitor of p38 combined with the interferon induction therapy elicits a robust anti-tumor effect. Thus, negative regulatory mechanisms of MDSC function can be exploited therapeutically.
MeSH term(s)	Adult ; Aged ; Aged, 80 and over ; Animals ; Antineoplastic Agents/pharmacology ; Bone Marrow ; Cell Line, Tumor ; Disease Models, Animal ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Interferon Type I/metabolism ; Male ; Mice ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; Mice, Knockout ; Middle Aged ; Monocytes/immunology ; Myeloid-Derived Suppressor Cells/immunology ; Neoplasms/metabolism ; Neutrophils/immunology ; Receptor, Interferon alpha-beta/genetics ; Receptor, Interferon alpha-beta/metabolism ; p38 Mitogen-Activated Protein Kinases/drug effects ; p38 Mitogen-Activated Protein Kinases/metabolism
Chemical Substances	Antineoplastic Agents ; IFNAR1 protein, human ; Ifnar1 protein, mouse ; Interferon Type I ; Receptor, Interferon alpha-beta (156986-95-7) ; p38 Mitogen-Activated Protein Kinases (EC 2.7.11.24)
Language	English
Publishing date	2021-03-19
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2553671-0
ISSN	2041-1723 ; 2041-1723
ISSN (online)	2041-1723
ISSN	2041-1723
DOI	10.1038/s41467-021-22033-2
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice.

The Journal of experimental medicine

2021 Volume 218, Issue 4

Abstract: In this study, using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, we characterized the heterogeneity of polymorphonuclear neutrophils (PMNs) in cancer. We describe three populations of PMNs in tumor-bearing mice: ... ...

Abstract	In this study, using single-cell RNA-seq, cell mass spectrometry, flow cytometry, and functional analysis, we characterized the heterogeneity of polymorphonuclear neutrophils (PMNs) in cancer. We describe three populations of PMNs in tumor-bearing mice: classical PMNs, polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), and activated PMN-MDSCs with potent immune suppressive activity. In spleens of mice, PMN-MDSCs gradually replaced PMNs during tumor progression. Activated PMN-MDSCs were found only in tumors, where they were present at the very early stages of the disease. These populations of PMNs in mice could be separated based on the expression of CD14. In peripheral blood of cancer patients, we identified two distinct populations of PMNs with characteristics of classical PMNs and PMN-MDSCs. The gene signature of tumor PMN-MDSCs was similar to that in mouse activated PMN-MDSCs and was closely associated with negative clinical outcome in cancer patients. Thus, we provide evidence that PMN-MDSCs are a distinct population of PMNs with unique features and potential for selective targeting opportunities.
MeSH term(s)	Animals ; Carcinoma, Lewis Lung/immunology ; Carcinoma, Lewis Lung/pathology ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/immunology ; Case-Control Studies ; Cell Line, Tumor ; Disease Models, Animal ; Female ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/immunology ; Lymphoma/immunology ; Lymphoma/pathology ; Mice ; Mice, Inbred C57BL ; Neutrophils/classification ; Neutrophils/immunology ; RNA-Seq ; Single-Cell Analysis ; Transcriptome
Language	English
Publishing date	2021-02-10
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	218343-2
ISSN	1540-9538 ; 0022-1007
ISSN (online)	1540-9538
ISSN	0022-1007
DOI	10.1084/jem.20201803
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.107: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MG 45: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.

Tcyganov, Evgenii N / Sanseviero, Emilio / Marvel, Douglas / Beer, Thomas / Tang, Hsin-Yao / Hembach, Peter / Speicher, David W / Zhang, Qianfei / Donthireddy, Laxminarasimha R / Mostafa, Ali / Tsyganova, Sabina / Pisarev, Vladimir / Laufer, Terri / Ignatov, Dmitriy / Ferrone, Soldano / Meyer, Christiane / Maby-El Hajjami, Hélène / Speiser, Daniel E / Altiok, Sooner /

Antonia, Scott / Xu, Xiaowei / Xu, Wei / Zheng, Cathy / Schuchter, Lynn M / Amaravadi, Ravi K / Mitchell, Tara C / Karakousis, Giorgos C / Yuan, Zhe / Montaner, Luis J / Celis, Esteban / Gabrilovich, Dmitry I

Cancer cell

2022 Volume 40, Issue 10, Page(s) 1173–1189.e6

Abstract: Cancer immunotherapy often depends on recognition of peptide epitopes by cytotoxic T lymphocytes (CTLs). The tumor microenvironment (TME) is enriched for peroxynitrite (PNT), a potent oxidant produced by infiltrating myeloid cells and some tumor cells. ... ...

Abstract	Cancer immunotherapy often depends on recognition of peptide epitopes by cytotoxic T lymphocytes (CTLs). The tumor microenvironment (TME) is enriched for peroxynitrite (PNT), a potent oxidant produced by infiltrating myeloid cells and some tumor cells. We demonstrate that PNT alters the profile of MHC class I bound peptides presented on tumor cells. Only CTLs specific for PNT-resistant peptides have a strong antitumor effect in vivo, whereas CTLs specific for PNT-sensitive peptides are not effective. Therapeutic targeting of PNT in mice reduces resistance of tumor cells to CTLs. Melanoma patients with low PNT activity in their tumors demonstrate a better clinical response to immunotherapy than patients with high PNT activity. Our data suggest that intratumoral PNT activity should be considered for the design of neoantigen-based therapy and also may be an important immunotherapeutic target.
MeSH term(s)	Animals ; Antigens, Neoplasm/metabolism ; Epitopes ; Histocompatibility Antigens Class I/metabolism ; Immunotherapy ; Melanoma/metabolism ; Mice ; Oxidants/metabolism ; Peptides ; Peroxynitrous Acid/metabolism ; T-Lymphocytes, Cytotoxic ; Tumor Microenvironment
Chemical Substances	Antigens, Neoplasm ; Epitopes ; Histocompatibility Antigens Class I ; Oxidants ; Peptides ; Peroxynitrous Acid (14691-52-2)
Language	English
Publishing date	2022-10-12
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2078448-X
ISSN	1878-3686 ; 1535-6108
ISSN (online)	1878-3686
ISSN	1535-6108
DOI	10.1016/j.ccell.2022.09.001
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5650: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MG 104: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito